Episode

Best of UEG Week - HPB with Carolin Schneider

Podcast
UEG Podcast
Published
Nov 11, 2025
Duration seconds
847
Processing state
not_requested
Canonical source
https://ueg-talks-podcast.podigee.io/62-new-episode
Audio
https://audio.podigee-cdn.net/2202695-m-7c25a79f4cfa5ca2741d76e8e356545f.mp3?source=feed
JSON
/v1/public/podcasts/ueg-podcast-6404464/episodes/best-of-ueg-week-hpb-with-carolin-schneider
Markdown
/podcast/ueg-podcast-6404464/best-of-ueg-week-hpb-with-carolin-schneider.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/ueg-podcast-6404464/episodes/best-of-ueg-week-hpb-with-carolin-schneider/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/ueg-podcast-6404464/best-of-ueg-week-hpb-with-carolin-schneider.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, UEG's new Scientific Committee chair Jörn Schattenberg and Carolin Schneider, UEG rising start of 2025, recap the standout science from UEG Week 2025 in Berlin. They discuss highlights from the HPB field, including pivotal phase III data on linerixibat for cholestatic pruritus in PBC, advances in MASLD/MASH therapies such as FGF21 analogues and resmetirom, and new insights into liquid biopsy and AI-assisted imaging for pancreatic lesions. The conversation also explores simvastatin’s potential in preventing recurrent pancreatitis and reflects on the value of collaboration, precision medicine, and prospective clinical trials showcased at UEG Week.